Andrew E Arai, Jeanette Schulz-Menger, Dipan J Shah, Yuchi Han, W Patricia Bandettini, Arun Abraham, Pamela K Woodard, Joseph B Selvanayagam, Christian Hamilton-Craig, Ru-San Tan, James Carr, Lynette Teo, Christopher M Kramer, Bernd J Wintersperger, Mukesh G Harisinghani, Scott D Flamm, Matthias G Friedrich, Igor Klem, Subha V Raman, Daniel Haverstock, Zheyu Liu, Guenther Brueggenwerth, Marta Santiuste, Daniel S Berman, Dudley J Pennell
BACKGROUND: GadaCAD2 was 1 of 2 international, multicenter, prospective, Phase 3 clinical trials that led to U.S. Food and Drug Administration approval of gadobutrol to assess myocardial perfusion and late gadolinium enhancement (LGE) in adults with known or suspected coronary artery disease (CAD). OBJECTIVES: A prespecified secondary objective was to determine if stress perfusion cardiovascular magnetic resonance (CMR) was noninferior to single-photon emission computed tomography (SPECT) for detecting significant CAD and for excluding significant CAD...
November 7, 2023: Journal of the American College of Cardiology